AAV5-hRKp.RPGR

BIOLOGICAL3 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Retinitis PigmentosaX-Linked Retinitis Pigmentosa

Phase 2

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Active, not recruitingNCT06646289

Janssen Research & Development, LLCX-Linked Retinitis Pigmentosa

Start: 2024-10-10End: 2030-10-24Updated: 2026-08-28

Phase 3

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Active, not recruitingNCT05926583

Janssen Pharmaceutical K.K.Retinitis Pigmentosa

Start: 2023-09-12End: 2030-11-12Updated: 2026-08-28

Unknown Phase

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

CompletedNCT04312672

Janssen Research & Development, LLCX-Linked Retinitis Pigmentosa

Start: 2017-07-31End: 2025-09-17Updated: 2026-01-21

Related Papers

Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.

2025-06-12